Pulse cyclophosphamide showed no clear difference in adverse events ‐ treatment failure compared with continuous cyclophosphamide (low certainty).
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
The review found no eligible studies for this question.
An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in infants with Severe Adverse Events compared with 1 week of antiretroviral prophylaxis (low certainty).
An extended antiretroviral regimen administered to mothers for 28… may leads to higher mothers with Severe Adverse Events compared with 1 week of antiretroviral prophylaxis (low certainty).
An extended NVP regimen administered to infants for 28 weeks showed no clear difference in infants with Severe Adverse Events compared with 1 week of antiretroviral prophylaxis (low certainty).
A once‐daily NVP regimen administered for 6 months showed no clear difference in infants with Severe Adverse Events compared with a once‐daily NVP regimen administered (high certainty).
An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in infants with Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).
An extended antiretroviral regimen administered to mothers for 28… may leads to higher mothers with Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
It is very uncertain whether percutaneous patellar osteosynthesis changes major adverse outcome: total events compared with open surgery (very low certainty).
Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.